Patent · US Active

Treatment of cancer using a CD33 chimeric antigen receptor

US12338287B2 · kind B2 · utility

0Cited by

45References

24Claims

0Family size

Assignees

Novartis AG · CH
The Trustees of the University of Pennsylvania · US

Inventors

Hilmar Erhard Ebersbach · Basel, CH
Thomas Huber · Basel, CH
Julia Jascur · Basel, CH
Celeste Richardson · Cambridge, US
Reshma Singh · Cambridge, US
Huijuan Song · Shanghai, CN
Qilong Wu · Shanghai, CN
Jiquan Zhang · Shanghai, CN

Key dates

Filing date	Oct 28, 2020
Grant date	Jun 24, 2025
Priority date	—
Expiry date	Jan 26, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.